Strategic Alternatives = Mo’ Money

Shares of Insignia Systems (ISIG) once again skyrocketed in Wednesday’s trading session closing the day up +84.1%. That brings the stock’s 5-day cumulative move to an astounding +247.8%. The catalyst for the move is the announcement that the firm has hired Chardan (an NY-based investment bank) to conduct a strategic review of their operations.
- Insignia Systems provides in-store digital point-of-purchase advertising displays for consumer packaged goods companies.
- The company has been hard hit by the pandemic, seeing its revenue decline in 9 of the last 11 quarters, and realizing a net loss in each of those quarters. In other words, they’re drowning and looking for a rescue boat.
- Increased competition and lower brand spending have been a drag on the company’s sales, and management expects continued weakness in the coming quarters.

Let’s review the last three trading days for $ISIG: Monday up +205%, Tuesday down -31% (most likely profit taking), and Wednesday up +84.1%. This has “buy the rumor, sell the news” written all over it. The stock is rallying on the announcement, which investors are looking at as a possible future merger or acquisition. It may be that the selloff comes once the board announces their plan of action. $ISIG was trading between $5-$10 before the current move. I am keeping the stock on my watchlist and waiting for a potential retracement back to $10 before I think of taking a long position.
Google Be Like…

Shares of Roku were higher Wednesday than your loser friend that still follows Phish around the country. The stock closed the session up at $256.08 (+18.23%) on an announcement that the company “has reached a multiyear agreement with Google to keep YouTube and YouTube TV on its streaming platform.” Terms of the deal were not disclosed, but today’s news puts an end to what has been a contentious negotiation regarding the future of YouTube and YouTube TV on the Roku platform.
- In April, Roku pulled the YouTube app from its channel store after failing to reach an agreement with the online cable service.
- Roku claimed that Google had “required it to prefer YouTube content over that of other providers in the company’s search results.” Google, of course, denied such accusations. Could you imagine a major Big Tech company like Google committing anything resembling anti-competitive tactics? *cue eye roll*
- Roku currently has 56.4M active accounts and a removal of YouTube and YouTube TV could have led to a mass exodus of customers to Amazon Fire or Apple TV, which both carry the ‘tube.

Even after today’s rally, $ROKU is still off its ATH of $490.76 by a measly 48%. Investors like nice round numbers, so it’s possible we see a sustained rally back to the $300 level before seeing another retracement. I will be watching for momentum above the swing close of $284.19 from May 6th before feeling confident the stock can reach the $300 mark.
You’re not going to believe this, but you need more shots

Pfizer whenever a new booster drops.^
Pfizer-BioNTech announced yesterday that a third dose of their vaccine is effectively able to neutralize the Omicron variant. That’s a relief, because the usual two doses offer just 4% of the protection they provide against other strains (and a 100% chance of sharing your location with Bill Gates). Just to be extra careful, Pfizer’s working on an Omicron-specific shot anyway, and thinks they’ll have that ready by March so that you’ll be healthy enough to fill out your bracket.
- Many believe the highly contagious Omicron variant is going to be the dominant COVID strain in the U.S. by spring. Thankfully, it also happens to be the one that doesn’t even lift, so your T-cells should have an easier time of whooping its a*s if you do get it.
- That’s just the current strain, though. As the outback’s (Australia, not Subaru) new “omicron-like” strain suggests, Omicron evolves rapidly enough that health authorities believe we’ll need an annual shot to protect ourselves from it, like the flu.
- Neither Pfizer nor BioNTech did so hot on the stock market despite this being fairly positive news. BioNTech had dipped 3.55% by markets’ close on Monday, while shares of Pfizer took a 0.62% hit.

This is a mixed bag for Pfizer and BioNTech. On the one hand, they’ve got the most promising solution to Omicron… On the other hand, it’s less a solution than a short-term fix, and what we know about COVID and rates of mutation suggests that there may never be a single long-term solution.